Literature DB >> 31953327

The small molecule GAT1508 activates brain-specific GIRK1/2 channel heteromers and facilitates conditioned fear extinction in rodents.

Yu Xu1, Lucas Cantwell1, Andrei I Molosh2, Leigh D Plant1, Dimitris Gazgalis1, Stephanie D Fitz2, Erik T Dustrude2, Yuchen Yang1, Takeharu Kawano1, Sumanta Garai1, Sami F Noujaim3, Anantha Shekhar4, Diomedes E Logothetis5, Ganesh A Thakur6.   

Abstract

G-protein-gated inwardly-rectifying K+ (GIRK) channels are targets of Gi/o-protein-signaling systems that inhibit cell excitability. GIRK channels exist as homotetramers (GIRK2 and GIRK4) or heterotetramers with nonfunctional homomeric subunits (GIRK1 and GIRK3). Although they have been implicated in multiple conditions, the lack of selective GIRK drugs that discriminate among the different GIRK channel subtypes has hampered investigations into their precise physiological relevance and therapeutic potential. Here, we report on a highly-specific, potent, and efficacious activator of brain GIRK1/2 channels. Using a chemical screen and electrophysiological assays, we found that this activator, the bromothiophene-substituted small molecule GAT1508, is specific for brain-expressed GIRK1/2 channels rather than for cardiac GIRK1/4 channels. Computational models predicted a GAT1508-binding site validated by experimental mutagenesis experiments, providing insights into how urea-based compounds engage distant GIRK1 residues required for channel activation. Furthermore, we provide computational and experimental evidence that GAT1508 is an allosteric modulator of channel-phosphatidylinositol 4,5-bisphosphate interactions. Through brain-slice electrophysiology, we show that subthreshold GAT1508 concentrations directly stimulate GIRK currents in the basolateral amygdala (BLA) and potentiate baclofen-induced currents. Of note, GAT1508 effectively extinguished conditioned fear in rodents and lacked cardiac and behavioral side effects, suggesting its potential for use in pharmacotherapy for post-traumatic stress disorder. In summary, our findings indicate that the small molecule GAT1508 has high specificity for brain GIRK1/2 channel subunits, directly or allosterically activates GIRK1/2 channels in the BLA, and facilitates fear extinction in a rodent model.
© 2020 Xu et al.

Entities:  

Keywords:  GIRK channels; PIP2; basolateral amygdala; medicinal chemistry; neurophysiology; phosphoinositide; potassium channel; small molecule; specific activator

Mesh:

Substances:

Year:  2020        PMID: 31953327      PMCID: PMC7076198          DOI: 10.1074/jbc.RA119.011527

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  75 in total

Review 1.  Emotion circuits in the brain.

Authors:  J E LeDoux
Journal:  Annu Rev Neurosci       Date:  2000       Impact factor: 12.449

2.  pi-Stacking interactions. Alive and well in proteins.

Authors:  G B McGaughey; M Gagné; A K Rappé
Journal:  J Biol Chem       Date:  1998-06-19       Impact factor: 5.157

3.  Heteromultimerization of G-protein-gated inwardly rectifying K+ channel proteins GIRK1 and GIRK2 and their altered expression in weaver brain.

Authors:  Y J Liao; Y N Jan; L Y Jan
Journal:  J Neurosci       Date:  1996-11-15       Impact factor: 6.167

4.  G-protein-coupled inwardly rectifying potassium channels are targets of alcohol action.

Authors:  J M Lewohl; W R Wilson; R D Mayfield; S J Brozowski; R A Morrisett; R A Harris
Journal:  Nat Neurosci       Date:  1999-12       Impact factor: 24.884

5.  Identification of structural elements involved in G protein gating of the GIRK1 potassium channel.

Authors:  P A Slesinger; E Reuveny; Y N Jan; L Y Jan
Journal:  Neuron       Date:  1995-11       Impact factor: 17.173

6.  The G-protein-gated atrial K+ channel IKACh is a heteromultimer of two inwardly rectifying K(+)-channel proteins.

Authors:  G Krapivinsky; E A Gordon; K Wickman; B Velimirović; L Krapivinsky; D E Clapham
Journal:  Nature       Date:  1995-03-09       Impact factor: 49.962

7.  G protein-gated inwardly rectifying potassium channels are targets for volatile anesthetics.

Authors:  L G Weigl; W Schreibmayer
Journal:  Mol Pharmacol       Date:  2001-08       Impact factor: 4.436

8.  Naringin directly activates inwardly rectifying potassium channels at an overlapping binding site to tertiapin-Q.

Authors:  Tin T Yow; Elena Pera; Nathan Absalom; Marika Heblinski; Graham A R Johnston; Jane R Hanrahan; Mary Chebib
Journal:  Br J Pharmacol       Date:  2011-07       Impact factor: 8.739

9.  Mechanisms underlying the activation of G-protein-gated inwardly rectifying K+ (GIRK) channels by the novel anxiolytic drug, ML297.

Authors:  Nicole Wydeven; Ezequiel Marron Fernandez de Velasco; Yu Du; Michael A Benneyworth; Matthew C Hearing; Rachel A Fischer; Mark John Thomas; C David Weaver; Kevin Wickman
Journal:  Proc Natl Acad Sci U S A       Date:  2014-07-07       Impact factor: 11.205

10.  Do Halogen-Hydrogen Bond Donor Interactions Dominate the Favorable Contribution of Halogens to Ligand-Protein Binding?

Authors:  Fang-Yu Lin; Alexander D MacKerell
Journal:  J Phys Chem B       Date:  2017-07-11       Impact factor: 2.991

View more
  10 in total

Review 1.  G protein-coupled receptor-effector macromolecular membrane assemblies (GEMMAs).

Authors:  Sergi Ferré; Francisco Ciruela; Carmen W Dessauer; Javier González-Maeso; Terence E Hébert; Ralf Jockers; Diomedes E Logothetis; Leonardo Pardo
Journal:  Pharmacol Ther       Date:  2021-09-01       Impact factor: 13.400

2.  Discovery, synthesis and biological characterization of a series of N-(1-(1,1-dioxidotetrahydrothiophen-3-yl)-3-methyl-1H-pyrazol-5-yl)acetamide ethers as novel GIRK1/2 potassium channel activators.

Authors:  Swagat Sharma; Lauren Lesiak; Christopher D Aretz; Yu Du; Sushil Kumar; Nagsen Gautam; Yazen Alnouti; Nikilesh V Dhuria; Yashpal S Chhonker; C David Weaver; Corey R Hopkins
Journal:  RSC Med Chem       Date:  2021-06-21

Review 3.  Neuronal G protein-gated K+ channels.

Authors:  Haichang Luo; Ezequiel Marron Fernandez de Velasco; Kevin Wickman
Journal:  Am J Physiol Cell Physiol       Date:  2022-06-15       Impact factor: 5.282

Review 4.  Advances in Targeting GIRK Channels in Disease.

Authors:  Yulin Zhao; Isabel Gameiro-Ros; Ian W Glaaser; Paul A Slesinger
Journal:  Trends Pharmacol Sci       Date:  2021-01-16       Impact factor: 14.819

5.  PIP2 regulation of TRPC5 channel activation and desensitization.

Authors:  Mehek Ningoo; Leigh D Plant; Anna Greka; Diomedes E Logothetis
Journal:  J Biol Chem       Date:  2021-04-29       Impact factor: 5.157

6.  Characterization of VU0468554, a New Selective Inhibitor of Cardiac G Protein-Gated Inwardly Rectifying K+ Channels.

Authors:  Allison Anderson; Baovi N Vo; Ezequiel Marron Fernandez de Velasco; Corey R Hopkins; C David Weaver; Kevin Wickman
Journal:  Mol Pharmacol       Date:  2021-09-09       Impact factor: 4.436

Review 7.  Next-generation inward rectifier potassium channel modulators: discovery and molecular pharmacology.

Authors:  C David Weaver; Jerod S Denton
Journal:  Am J Physiol Cell Physiol       Date:  2021-04-07       Impact factor: 5.282

8.  AsKC11, a Kunitz Peptide from Anemonia sulcata, Is a Novel Activator of G Protein-Coupled Inward-Rectifier Potassium Channels.

Authors:  Dongchen An; Ernesto Lopes Pinheiro-Junior; László Béress; Irina Gladkikh; Elena Leychenko; Eivind A B Undheim; Steve Peigneur; Jan Tytgat
Journal:  Mar Drugs       Date:  2022-02-15       Impact factor: 5.118

9.  A novel small-molecule selective activator of homomeric GIRK4 channels.

Authors:  Meng Cui; Keman Xu; Kirin D Gada; Boris Shalomov; Michelle Ban; Giasemi C Eptaminitaki; Takeharu Kawano; Leigh D Plant; Nathan Dascal; Diomedes E Logothetis
Journal:  J Biol Chem       Date:  2022-05-04       Impact factor: 5.486

10.  Hypoxia inhibits the cardiac I K1 current through SUMO targeting Kir2.1 activation by PIP2.

Authors:  Yu Xu; Yuchen Yang; Aishwarya Chandrashekar; Kirin D Gada; Meghan Masotti; Austin M Baggetta; Jenna G Connolly; Takeharu Kawano; Leigh D Plant
Journal:  iScience       Date:  2022-08-17
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.